Literature DB >> 31009664

A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.

Jacqueline McKesey1, Amit G Pandya2.   

Abstract

Entities:  

Year:  2019        PMID： 31009664     DOI： 10.1016/j.jaad.2019.04.032

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  7 in total

Review 1.  A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo.

Authors:  Christopher White; Richard Miller
Journal:  J Clin Aesthet Dermatol       Date:  2022-04

2.  Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo.

Authors:  P Mobasher; R Guerra; S J Li; J Frangos; A K Ganesan; V Huang
Journal:  Br J Dermatol       Date:  2019-12-05       Impact factor: 9.302

Review 3.  Vitiligo, From Physiopathology to Emerging Treatments: A Review.

Authors:  Laure Migayron; Katia Boniface; Julien Seneschal
Journal:  Dermatol Ther (Heidelb)       Date:  2020-09-19

4.  Repigmentation of vitiligo-associated eyelash leukotrichia with topical tofacitinib.

Authors:  Sa Rang Kim; Brittany G Craiglow
Journal:  JAAD Case Rep       Date:  2021-07-27

Review 5.  Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.

Authors:  Paolo Custurone; Luca Di Bartolomeo; Natasha Irrera; Francesco Borgia; Domenica Altavilla; Alessandra Bitto; Giovanni Pallio; Francesco Squadrito; Mario Vaccaro
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

Review 6.  Current Concepts of Vitiligo Immunopathogenesis.

Authors:  Nika Hlača; Tina Žagar; Marija Kaštelan; Ines Brajac; Larisa Prpić-Massari
Journal:  Biomedicines       Date:  2022-07-08

7.  Reliability and validity of the Vitiligo Signs of Activity Score (VSAS).

Authors:  N van Geel; T Passeron; A Wolkerstorfer; R Speeckaert; K Ezzedine
Journal:  Br J Dermatol       Date:  2020-03-29       Impact factor: 9.302
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.